Navigation Links
ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
Date:2/28/2017

ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of novel pharmaceuticals for the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. With more than 15 years of clinical development experience with a number of multinational drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, President, to continue advancing the company’s lead drug candidate, AC0010. The drug candidate is currently in clinical trials for the treatment of non-small cell lung cancer (NSCLC) in both China and the US. A pyrrolopyrimidine-based irreversible inhibitor of the EGFR tyrosine kinase, AC0010 provides NSCLC patients with a new treatment alternative should first generation EGFR tyrosine kinase inhibitors fail to produce a durable response. Thus far, AC0010 has demonstrated efficacy, tolerability, and safety in clinical trials in both China and the U.S. Global clinical trials are slated for late 2017.

Before joining ACEA, Dr. Luo was Compound Development Team Lead, and Senior Leadership Member of Exploratory Medicine and Early Development at Johnson & Johnson (JNJ). Prior to JNJ, he was the Sr. Director of Early Clinical Development at Daiichi-Sankyo, and Head of the Tumor Pharmacology Group at Bristol-Myers Squibb. In total, Dr. Luo has participated in more than 20 oncology drug development trials around the globe, and has particular expertise in lung cancer therapeutics. “We are thrilled to have Roger join ACEA at this critical phase of the company’s history,” said Xiao Xu. “Roger’s experience and proficiency in drug development will be a major asset as we usher AC0010 through clinical trials.”

For more information about ACEA Biosciences, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: +1 858 724 0928 x 3075                                                                                                
email: jxue(at)aceabio(dot)com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14105641.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. Northstar Biosciences Launches All Natural Skincare Solutions
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
7. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... R3 Stem ... injections for only $3950. With 50 million stem cells total, patients may choose which ... cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical ...
(Date:7/31/2020)... ... 2020 , ... Anomet Products has introduced new custom composite ... with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad Wire ... and cost criteria; especially where solid wire is limited. Typical configurations for implantable ...
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter ... great surgery is only the beginning of a successful study, while protecting and accessing ... Brad Gien, Global Head of Surgery from Envigo in a live ...
Breaking Biology Technology:
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, ... the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga ... supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm ... XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study ...
Breaking Biology News(10 mins):